Skip to main content
TeamingIndex
Unclaimed profileSeeded from SAM.gov and USAspending public records

NOVOMEDIX LLC

UEIXQYMHKGDMU75CAGE4C2X1NAICS541714
  • SAM active
  • No verified credentials yet
  • CMMCNot on file
  • SPRSNone
  • FCLVisible to paid members
  • Small Business
  • Women-Owned Small Business

Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works

36-mo obligations
$0
Awards on record
0
Contract vehicles
0
Verified credentials
0

Compliance posture: unverified (SAM.gov baseline only)

NOVOMEDIX LLC has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0

Claim this profile

About NOVOMEDIX LLC

NOVOMEDIX LLC is a SAM.gov-registered entity based in SAN DIEGO, CA 92126-6361. UEI XQYMHKGDMU75; CAGE 4C2X1; primary NAICS 541714. Compliance posture not provided. Active SAM registration.
Headquarters
SAN DIEGO, CA 92126-6361

Identifiers

UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.

  • UEIXQYMHKGDMU75
  • CAGE4C2X1

Capabilities & differentiators

No capability narrative yet

The company has not published a capability narrative. Its SAM.gov registration, NAICS codes and award history are below.

Compliance posture

Every credential shows who vouches for it: verified by TeamingIndex, or self-attested by the contractor.

No compliance posture published yet

Compliance facts appear once the company claims this profile and publishes them.

Facility clearance

Facility clearance: visible to paid members

Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans

No federal prime awards on record

USAspending shows no prime awards for this UEI in the last 36 months. Subcontract work does not appear here.

No contract vehicles on file

This company has not listed GWAC, IDIQ, GSA Schedule or OTA consortium holdings.
Who NOVOMEDIX LLC has actually worked with, from sub-awards that prime contractors report to the government. Use it to see which primes already trust this company.

No sub-award reports yet

Prime contractors report first-tier subcontracts of $30,000 or more. None name this company yet, which is common for companies that mostly win prime contracts or work below the reporting threshold.

Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.

Small Business Innovation Research and Technology Transfer awards: early-stage federal R&D money this company has won.

SBIR/STTR awardee — Phase III-eligible for work derived from its SBIR/STTR projects

Agencies may award follow-on Phase III work without a new competition when it builds on this company’s earlier SBIR/STTR projects. Other work is competed as usual.

Awards on record
13 awards
Total awarded
$10,613,686
By phase
  • SBIR Phase I: 9
  • SBIR Phase II: 4
By agency
  • Department of Health and Human Services: 13
Active projects
0 projects
Projects whose contract end date is today or later.
Phase II ending within 12 months
0 projects
Phase II projects ending within 12 months. Agencies may award Phase III work without a new competition only when it derives from, extends or completes these projects.
By year
  • 2025: 2
  • 2024: 2
  • 2022: 2
  • 2021: 1
  • 2019: 1
  • 2016: 1
  • 2012: 2
  • 2010: 1
  • 2007: 1

Awards (most recent first)

  • Arthrofibrosis control using small molecule inhibitors of interleukin-11

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2025 · $314,362

    Sep 22, 2025 – Aug 31, 2026

    Solicitation PA24-245 (2024) · Topic NIAMS

  • NOVOMEDIX TRANSITION TO PHASE II - THERAPEUTICS SBIR CONTRACTSBIR PHASE II - ENHANCED OVERALL SURVIVAL IN HIGH-RISK PEDIATRIC SOLID TUMORS USING A NOVEL ORAL SMALL MOLECULE

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2025 · $2,977,013

    • Direct to Phase II

    Solicitation 75N91024R00019 (2024) · Topic Transition PHII

  • Novel oral small molecules for progressive pulmonary fibrosis

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2024 · $306,872

    Sep 20, 2024 – Feb 28, 2025

    Solicitation PA23-230 (2023) · Topic NHLBI

  • Definitive (GLP) Toxicity and Toxicology Studies for a Novel Small Molecule for Protection Against Cardiotoxicity in Triple Negative Breast Cancer

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $500,000

    Sep 15, 2024 – Aug 31, 2025

    Solicitation PAR23-219 (2023) · Topic NHLBI

  • Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $1,993,505

    May 16, 2022 – Apr 30, 2024

    • Direct to Phase II

    Solicitation PA21-259 (2021) · Topic NHLBI

  • SBIR CONCEPT AWARD TO NOVOMEDIX- NOVEL SMALL MOLECULES FOR THE TREATMENT OF RHABDOMYOSARCOMA

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2022 · $355,000

    Solicitation 75N91020R00043 (2021) · Topic NCICA22

  • Novel Therapy for Protection against Diabetes and its Complications in Ischemic Heart Disease

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $375,000

    Sep 1, 2021 – Aug 31, 2022

    Solicitation PA20-260 (2020) · Topic NHLBI

  • Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2019 · $375,001

    Sep 19, 2019 – Aug 31, 2020

    Solicitation PA18-574 (2018) · Topic NHLBI

  • Novel antifibrotic small molecules for the treatment of heart failure

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $300,000

    Apr 1, 2016 – Mar 31, 2018

    Solicitation PA15-269 (2015) · Topic NHLBI

  • Development of novel small molecule drugs for the treatment of high risk B-ALL

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $300,000

    Solicitation PA11-096 (2012) · Topic NCI · Research partner: Stub

  • The optimization of compounds that selectively inhibit protein synthesis for the

    SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2012 · $2,000,000

    Solicitation PA11-096 (2012) · Topic NCI · Research partner: Stub

  • Optimization of compounds that selectively inhibit protein synthesis for the trea

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2010 · $300,236

    Solicitation PHS2010-2 (2010) · Topic NCI

  • Discovery and Development of Compounds to Enhance b-cell Number and Function

    SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2007 · $516,697

    Solicitation year 2007

Source: SBIR.gov award data file (opens in a new tab) · as of Nov 12, 2026 · file published Nov 1, 2026

Cloud services this company lists on the FedRAMP Marketplace, the government's record of cloud authorizations.

No FedRAMP Marketplace listing

No FedRAMP Marketplace listing is linked to this company. Cloud providers appear here automatically once FedRAMP lists their offering.

Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded

Checks a prime runs before teaming: SAM.gov exclusions (debarment and suspension) and the government's Consolidated Screening List for export and sanctions lists.

SAM.gov exclusions

Not yet checked against SAM.gov exclusions.

Search exclusions on SAM.gov (opens in a new tab)

Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.

Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded

Consolidated Screening List

No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).

The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.

Hourly ceiling rates this company was awarded on GSA contracts, compared with the market for similar labor categories. Ceiling rates are the most an agency can be charged, not prices paid.

No GSA CALC+ rates on record

Companies with a GSA Multiple Award Schedule contract appear here after CALC+ publishes their awarded labor rates.

NAICS, PSC & socio-economic status

Industry codes and small-business programs reported in SAM.gov.

NAICS codes

  • 541714Research and Development in Biotechnology (except Nanobiotechnology)PrimarySmall business under this code’s size standard

SAM.gov reports this entity as small under 1 of 1 NAICS code. Size is determined per code (SBA size standards).

Socio-economic status

Self-represented in SAM.gov. WOSB and EDWOSB set-asides need SBA certification (13 CFR 127.300); SDVOSB and VOSB need SBA VetCert (13 CFR part 128). Confirm current certification before relying on it.

Learn more about small business set-asides

Product & service codes (PSC)

No PSC codes reported.

This company has not published teaming preferences.

SAM.gov teaming eligibility: Eligible to be proposed as a team member: active SAM.gov registration and no exclusion.

Business development contact

No BD contact published

Contact details appear once the company claims this profile.
Immediate parent and highest-level owner as reported in SAM.gov.

No parent entity reported in SAM.gov.

SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.

Data sources & provenance

Who stands behind each fact on this page, and how to correct it.
  • SAM.gov

    Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.

  • USAspending.gov

    Prime award history and obligations (FPDS), synced nightly.

  • The contractor

    Nothing yet: this profile has not been claimed by the company.

  • TeamingIndex verification

    Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.

Corrections

Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)

Machine-readable: capability.md schema.org JSON-LD embedded in this page.

Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.

Teaming

Ready to team with NOVOMEDIX LLC?

Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.